Fidelity Management & Research, an American multinational financial services corporation, led a $115m financial round in Kardium, a provider of medical devices, with participation from T. Rowe Price Group, an American publicly owned global investment management firm. “We are tremendously excited to have Fidelity Management & Research Company join Kardium as a major investor, along with the T. Rowe Price funds. Their enthusiasm and support reflect the incredible success we have achieved with the Globe System and the potential we have to dramatically improve the treatment of atrial fibrillation for millions of patients worldwide. This financial backing now allows us to accelerate commercial sales in Europe and begin the FDA study for the Globe System,” Kevin Chaplin, Kardium CEO.